Strategic Shift to US Operations

These large commitments mark a strategic shift for Indian corporations, moving beyond export-driven growth to gain direct operational control and integration in key U.S. industries. Pharma sector consolidation, led by Sun Pharma's acquisition, shows a planned strategy to use existing U.S. infrastructure and market access. This aligns with U.S. goals for supply chain resilience and addressing domestic drug shortages.

Pharma Sector Leads Acquisitions

The pharmaceutical sector's $19.1 billion pledge is largely driven by Sun Pharmaceutical Industries' $11.75 billion acquisition of Organon & Co. This acquisition nearly doubles Sun Pharma's revenue to an estimated $12 billion, placing it among the top 25 global pharmaceutical companies. Organon, expected to have $6.2 billion in 2025 revenue and strong positions in women's health and biosimilars, offers Sun Pharma immediate scale and market entry into these growing areas. The strategy aims to boost Sun Pharma's global reach and diversify revenue, easing pressures from generic price erosion in the U.S. market, where growth is projected at 3-5% in FY26 versus 8-10% domestically. Other Indian pharma companies like Aurobindo Pharma, Biocon Group, Cipla, and Dr. Reddy's Laboratories are also investing. They plan to expand manufacturing, R&D, and specialty capabilities to help address U.S. drug shortages and strengthen supply chains. The U.S. market remains critical, accounting for approximately 40% of India's generic drug supply. Analysts note persistent price erosion and competition in U.S. generics, pointing to Sun Pharma's P/E of 28x compared to Piramal Pharma's 45x.

Manufacturing and Tech Boost Supply Chains

Investments in manufacturing and technology show a wider effort to strengthen supply chains. Abhyuday Group's $900 million pledge for manufacturing clusters across five U.S. states is the largest single manufacturing commitment, aiming to create 1,500 American jobs. JSW Steel USA is investing $110 million in its Baytown, Texas, facility and $145 million in Mingo Junction, Ohio. The funds will modernize steel plate mills with sustainable technology, focusing on products for renewable energy and infrastructure sectors, in line with 'Buy America' policies. Sterlite Technologies is committing up to $100 million for a U.S. factory producing AI-driven data center connectivity solutions. This positions the company to benefit from U.S. broadband infrastructure programs like BEAD. The IIT Madras Global Research Foundation is investing $4.5 million for a California hub to foster deep-tech innovation and support Indian startups entering global markets. This complements U.S. efforts in technological advancement. These initiatives help the U.S. diversify supply chains away from overreliance on China and strengthen domestic industrial capacity.

Challenges Ahead: Regulatory and Market Hurdles

Despite these large investment pledges, Indian firms face significant challenges in the U.S. market. The pharmaceutical sector, expanding its U.S. presence through acquisitions, faces ongoing price erosion in generics and rising competition. This has led to slower growth projections for U.S. revenues. Sun Pharma's specialty business is growing but adoption is slower than expected, and its core generics portfolio is still vulnerable to intense pricing pressures. Scrutiny from the U.S. FDA, including warning letters and import alerts, poses ongoing risks that can delay product launches and affect profitability. Additionally, the possibility of U.S. pharmaceutical tariffs, though currently lessened by trade deals, introduces policy uncertainty. For complex acquisitions like Sun Pharma's Organon deal, integration risks and managing significant debt (projected Net Debt/EBITDA of 2.3x) are critical.

Historically, Indian investment in the U.S. has grown, but India has invested less in the U.S. compared to U.S. investment in India.

US-India Trade Goals and Future Outlook

These investments align with the broader U.S.-India bilateral trade goal of reaching $500 billion by 2030, supported by ongoing talks for a comprehensive trade agreement. The proposed agreement aims to provide greater policy clarity and reduce tariffs, potentially boosting the competitiveness of Indian exports, including pharmaceuticals. The U.S. administration sees these investments as vital for strengthening supply chains and creating jobs, reflecting a mutually beneficial economic relationship. Analysts expect continued growth for the Indian pharmaceutical sector, though with a more moderate outlook for the U.S. market. They stress the need for companies to balance domestic strengths with international expansion while navigating changing regulatory and market conditions. The total $20.5 billion in commitments is the largest single-country investment showcase in SelectUSA's history. It signals a deepening economic partnership and an aggressive move by Indian firms to establish a stronger presence in the U.S.